3billion and Seoul National University Hospital Rare Disease Center Collaborate to Advance Precision Medicine for Rare Diseases

3billion, an AI-based rare disease diagnostics company (CEO Kim Chang-won), and the Seoul National University Hospital (SNUH) Rare Disease Center (Director Prof. Chae Jong-hee) announced on the 23rd that they signed a Memorandum of Understanding (MOU) on September 22 to collaborate on genomic diagnostics and therapeutic development for rare diseases.

The agreement aims to jointly promote early diagnosis of rare genetic disorders and the development of personalized treatments. Key areas of cooperation include:

• Development and clinical validation of genomic testing technologies
• Research and development of new drugs and therapies
• Expansion of clinical research and academic exchange

By combining 3billion’s advanced genomic interpretation technology with SNUH Rare Disease Center’s extensive clinical expertise and patient care capabilities, the partnership is expected to significantly strengthen global competitiveness in the field of rare disease diagnostics and treatment.

As a leading medical institution in rare disease care, the SNUH Rare Disease Center has built integrated clinical-genomic capabilities for precision diagnostics and preventive strategies. Its research spans molecular diagnostics, genetic and genomic testing, and clinical validation of novel therapeutics. When combined with 3billion’s variant interpretation platform, these strengths are expected to accelerate more accurate genomic diagnoses and patient-specific therapy development, serving as a key infrastructure for innovation.

The signing ceremony was attended by 3billion’s CEO Kim Chang-won, principal clinical research leaders, and representatives from SNUH Rare Disease Center. Both parties plan to broaden the scope of their cooperation through joint research projects.

Prof. Chae Jong-hee, Director of the Rare Disease Center, stated:
“By combining Seoul National University Hospital’s large-scale clinical and genomic integration data with 3billion’s innovative diagnostic capabilities, we can achieve world-class outcomes in precision medicine for rare diseases. We expect this partnership to deliver tangible results that go beyond research collaboration to directly benefit patient diagnosis, treatment, and prevention.”

Kim Chang-won, CEO of 3billion, added:
“We look forward to creating meaningful outcomes by merging clinical expertise with research and development capabilities. This collaboration will establish a new model for precision medicine research in rare diseases, contributing to medical innovation both domestically and globally.”